Exact Sciences (EXAS) Posts Smaller Q1 Loss
Get Alerts EXAS Hot Sheet
EPS Growth %: -14.3%
Financial Fact:
Interest income: 535K
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.18), $0.85 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $402.1 million versus the consensus estimate of $388.57 million.
"The first quarter demonstrated Exact Sciences is well-positioned for growth today and into the future," said Kevin Conroy, Chairman and CEO. "Our Cologuard® and Oncotype® tests help people in need of answers, including those who have been vulnerable during the pandemic. We plan to bring additional solutions to patients throughout the course of their diagnosis and treatment."
GUIDANCE:
Exact Sciences sees Q2 2021 revenue of $1.69-1.735 billion, versus the consensus of $1.72 billion.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
- Franklin Covey (FC) Tops Q2 EPS by 1c, Misses on Revenue; Offers Guidance
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!